Fairmed Healthcare’s Oren Weininger has been appointed as chairman of the board of Strides Pharma International AG

Indian pharmaceutical company Strides Pharma Science Limited has announced the consolidation of its European business through Strides Pharma International AG, based in Zug, Switzerland.

Headquartered in Bangalore, Strides Pharma is a leading manufacturer of active pharmaceutical ingredients (APIs) and diverse pharmaceutical products. Notably, it is among the world’s largest manufacturers of Ibuprofen and Macrogol in various forms.

The company has a global manufacturing footprint with eight facilities spread across four continents and a strong presence in 100 countries.

Oren Weininger, the longstanding leader of Fairmed Healthcare, has been appointed as the CEO and Chairman of the Board of Strides Pharma International AG.

Highlighting the company’s strategic move, Weininger stated, “With this strengthened European B2B presence, we can respond faster to our customers’ needs and provide flexible, innovative solutions, and interesting generic portfolio, including comprehensive support in supply chain and quality management and regulatory processes by Strides Pharma International and the EU GMP-site in Hamburg, Germany.”

The company’s key markets in Europe include Central and Southern Europe (especially Germany), Scandinavia, Benelux, and the Visegrád countries.

Weininger comes with vast experience in the pharmaceutical industry, including roles at Dexcel Pharma and Kamedis before he became CEO of Fairmed Healthcare AG in 2014. He later acquired the company in 2018.

Strides Pharma, after a period of successful partnership with Fairmed Healthcare, invested in the company in 2019, further bolstering its leading product lines.

Alongside his role at Strides Pharma International AG, Weininger continues to lead Fairmed Healthcare GmbH in Hamburg.

Strides Pharma’s partner-centric in-licensing portfolio of over 250 formulations is consolidated in synergICE as a one-stop shop. It includes generics, sterile injectables, value-added products, women’s health hormones, lyophilized orally dissolving tablets and end-to-end biopharmaceutical CDMO services.